BACKGROUND: Very few studies assessed cholangiocarcinoma clinical characteristics. AIM: To evaluate the clinical characteristics of intra-hepatic (IH) and extra-hepatic (EH)-CCA. METHODS: We performed a national survey based on a questionnaire. RESULTS: 218 cholangiocarcinomas were observed (47% EH-CCA, 53% IH-CCA) with an age at the diagnosis higher for EH-CCA. Coexistence of cirrhosis or viral cirrhosis was more frequent in IH-CCA than EH-CCA. An incidental asymptomatic presentation occurred in 28% of IH-CCA vs 4% EH-CCA whilst, 74% EH-CCA vs 28% IH-CCA presented with jaundice. 91% of IH-CCA presented as a single intra-hepatic mass, whilst 50% of EH-CCA was peri-hilar. In the diagnostic work-up, 70% of all cholangiocarcinoma ca...
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incide...
Background and aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, with incre...
Cholangiocarcinoma (CCA) is a rare biliary tract epithelial malignancy. We described the clinical fe...
Background: Very few studies assessed cholangiocarcinoma clinical characteristics. Aim: To evaluate ...
We report the results of a survey promoted in Italy by the AISF“Cholangiocarcinoma” (CCA) committee ...
BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. AIM: We fo...
Abstract BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. ...
The incidence of Cholangiocellular carcinoma (CCA) is increasing, due to a sharp increase of the int...
Cholangiocarcinoma (CCA) is a very heterogeneous cancer in many aspects including epidemiology, risk...
Background: Comprehensive and contemporary data pertaining large populations of patients with Primar...
SummaryCholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis ...
Background & Aims: Management of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is not we...
Cholangiocarcinoma (CCA) is a malignant tumour that arises from biliary epithelium at any portion of...
Background: Intrahepatic cholangiocarcinoma (ICC) is an unusual tumour. Methods: The clinicopatholo...
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose in...
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incide...
Background and aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, with incre...
Cholangiocarcinoma (CCA) is a rare biliary tract epithelial malignancy. We described the clinical fe...
Background: Very few studies assessed cholangiocarcinoma clinical characteristics. Aim: To evaluate ...
We report the results of a survey promoted in Italy by the AISF“Cholangiocarcinoma” (CCA) committee ...
BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. AIM: We fo...
Abstract BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. ...
The incidence of Cholangiocellular carcinoma (CCA) is increasing, due to a sharp increase of the int...
Cholangiocarcinoma (CCA) is a very heterogeneous cancer in many aspects including epidemiology, risk...
Background: Comprehensive and contemporary data pertaining large populations of patients with Primar...
SummaryCholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis ...
Background & Aims: Management of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is not we...
Cholangiocarcinoma (CCA) is a malignant tumour that arises from biliary epithelium at any portion of...
Background: Intrahepatic cholangiocarcinoma (ICC) is an unusual tumour. Methods: The clinicopatholo...
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose in...
Background & Aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incide...
Background and aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, with incre...
Cholangiocarcinoma (CCA) is a rare biliary tract epithelial malignancy. We described the clinical fe...